Skip to main content

Table 2 Multivariable Cox regression analysis for distant disease-free survival

From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Covariable

Distant disease-free survivalHR (95% CI)

P

CXCL13 expression

 ≤ Median

ref.

 

 > Median

0.44 (0.29–0.67)

< 0.001

FOXP3 expression

  ≤ Median

ref.

0.400

 > Median

1.20 (0.78–1.84)

 

CD4 expression

  ≤ Median

ref.

0.396

 > Median

1.89 (0.80–1.78)

 

Age at study entry

 ≤50 years

Ref.

0.516

 >50 years

0.88 (0.62–1.27)

 

Tumor size

 

0.105

 pT1

Ref.

 

 pT2

1.22 (0.82–1.81)

0.330

 pT3

1.89 (1.05–3.40)

0.034

Axillary nodal status

 

< 0.001

 pN0

Ref.

 

 pN1

4.51 (1.94–10.52)

< 0.001

 pN2

14.27 (4.78–42.71)

< 0.001

Histological grade

 

0.229

 I

Ref.

 

 II

2.06 (0.86–4.95)

0.105

 III

2.22 (0.88–5.52)

0.088

Molecular subtype

 

< 0.001

 Luminal A-like

Ref.

 

 Luminal B-like

1.79 (1.01–3.14)

0.045

 Triple-negative

4.18 (2.30–7.59)

< 0.001

 HER2-positive

2.71 (1.56–4.68)

< 0.001

  1. Abbreviations: CD4 cluster of differentiation 4, CI confidence interval, CXCL13 C-X-C motif chemokine ligand 13, FOXP3 forkhead box P3, HER2 human epidermal growth factor receptor 2, HR hazard ratio